During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

spinout founded in 2015 by CAR-T pioneers Carl June and Bruce Levine – for an undisclosed amount. AstraZeneca and Ionis add an EU green light to earlier approvals in the US and UK for ATTR ...

Despite the impressive results seen in immunology, and the US Food and Drug Administration approvals for two CAR-T treatments ... AstraZeneca and Ionis add an EU green light to earlier approvals ...

Automobile stocks led the declines on Wednesday following U.S. President Donald Trump’s remarks about tariffs on cars. Limiting losses ... Remitly Global (RELY), Grand Canyon Education (LOPE), Ionis ...

Automobile stocks led the declines on Wednesday following U.S. President Donald Trump’s remarks about tariffs on cars. Limiting losses ... Canyon Education (LOPE), Ionis Pharma (IONS), Krystal ...

Ionis Pharmaceuticals' Q4 earnings beat expectations, but guidance for 2025 was slightly below consensus, leading to a HOLD rating pending further catalysts. TRYNGOLZA's approval for FCS is ...

It wasn’t until late last year, 35 years into its history, that Ionis Pharmaceuticals earned FDA approval for the first drug it’ll be commercializing on its own rather than with the help of a ...

Richard Geary; Executive Vice President, Chief Development Officer; Ionis Pharmaceuticals Inc Elizabeth Hougen; Chief Financial Officer, Executive Vice President - Finance; Ionis Pharmaceuticals ...

Ionis reported Q4 EPS loss of $(0.66), beating estimates, with revenue of $227M, surpassing the $137.6M consensus despite a YoY decline. The company ended 2024 with $2.3B in cash, exceeding ...

Ionis Pharmaceuticals (NASDAQ:IONS), a leader in RNA-targeted drug discovery and development, announced its earnings results for the fourth quarter on Feb. 19. The report revealed that Ionis ...